Synthesis and properties of magnetosensitive nanocomposites and ferrofluids based on magnetite, gemcitabine and HER2 antibody

被引:1
|
作者
Abramov, M., V [1 ]
Petranovska, A. L. [1 ]
Kusyak, N., V [2 ]
Kusyak, A. P. [2 ]
Korniichuk, N. M. [1 ]
Turanska, S. P. [1 ]
Gorbyk, P. P. [1 ]
Luk'yanova, N. Yu [3 ]
Chekhun, V. F. [3 ]
机构
[1] Natl Acad Sci Ukraine, O Chuiko Inst Surface Chem, 17 Gen Naumov Str, UA-03164 Kiev, Ukraine
[2] I Franko Zhytomyr State Univ, 40 V Berdychevska Str, UA-10008 Zhytomyr, Ukraine
[3] Natl Acad Sci Ukraine, B Kavetsky Inst Expt Pathol Oncol & Radiobiol, 45 Vasylkivska Str, UA-03022 Kiev, Ukraine
来源
FUNCTIONAL MATERIALS | 2020年 / 27卷 / 02期
关键词
adsorption; gemcitabine; nanosized single-domain magnetite; core-shell nanocomposites; ferrofluids; her2; antibody; CELLS;
D O I
10.15407/fm27.02.283
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
The processes of adsorption of gemcitabine (GEM) on a surface of nanosized single-domain magnetite (Fe3O4) and magnetic properties of Fe3O4@GEM nanocomposites (NC) have been investigated. Ferrofluids (FF) were synthesized based on magnetite and physiological solution (PS), stabilized with sodium oleate (O1.Na) and polyethylene glycol (PEG), containing GEM (Fe3O4@GEM/O1.Na/PEG+PS). The properties of FF were investigated, as well as cytotoxic/cytostatic activity with respect to HepG2 hepatocellular carcinoma (HCC) cells of human liver. It was revealed that the complex action of GEM and her2 antibody (AB) in composition of FF Fe3O4@GEM/O1.Na/PEG+PS+HER2 onto HepG2 cells caused the synergistic effect and an increase in cytotoxic activity by similar to 18-20 %, compared to GEM in mono-use, with a considerable decrease in its concentration.
引用
收藏
页码:283 / 295
页数:13
相关论文
共 50 条
  • [41] Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice
    Sadri-Ardalani, Fateme
    Ahmadi, Moslem
    Hemmati, Azam
    Emami, Shaghayegh
    Farid, Samira
    Amiri, Mohammad Mehdi
    Jeddi-Tehrani, Mahmood
    Shabani, Mahdi
    Shokri, Fazel
    IRANIAN JOURNAL OF IMMUNOLOGY, 2017, 14 (02) : 99 - 110
  • [42] Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
    Abelman, Rachel Occhiogrosso
    Medford, Arielle
    Spring, Laura
    Bardia, Aditya
    CANCER JOURNAL, 2022, 28 (06): : 423 - 428
  • [43] Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2
    Lam, XM
    Yang, JY
    Cleland, JL
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (11) : 1250 - 1255
  • [44] Sensitive and electroactive surface development for electrochemical HER2 detection based on CS@CeO2/MWCNTs nanocomposites
    Kayani, Farrukh Bashir
    Rafique, Saima
    Ullah, Hushmat
    Afrin, Rahat
    JOURNAL OF MATERIALS RESEARCH, 2024, 39 (9) : 1384 - 1395
  • [45] Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody
    Yu, Xiaojie
    Wang, Lingfei
    Shen, Yafeng
    Wang, Chao
    Zhang, Yajun
    Meng, Yanchun
    Yang, Yang
    Liang, Beibei
    Zhou, Bo
    Wang, Huajing
    Wei, Huafeng
    Lei, Changhai
    Hu, Shi
    Li, Bohua
    MOLECULAR IMMUNOLOGY, 2017, 87 : 300 - 307
  • [46] Long term survival of metastatic HER2 positive breast cancer patients with no radiographic evidence of disease (NED) on HER2 antibody therapy
    Bennett, Alexis
    Chen, Zhengyi
    Martin, James
    Mallat, Naji
    Fu, Pingfu
    Montero, Alberto
    CANCER RESEARCH, 2024, 84 (09)
  • [47] Anti HER2 rabbit monoclonal antibody SP3 is a better predictor of HER2 gene status in invasive breast carcinoma
    Orvieto, E.
    Zanatta, L.
    Rossi, S.
    Furlanetto, A.
    Canal, F.
    Laurino, L.
    Dei Tos, A. P.
    MODERN PATHOLOGY, 2007, 20 : 44A - 44A
  • [48] Comparison between the Bond Oracle HER2 immunohistochemical system, the polyclonal HER2 Dako antibody and Chromogenic In Situ Hybridization in breast carcinoma
    Kourea, H.
    Tzelepi, V.
    Nikolatou, I.
    Ravazoula, P.
    Zolota, V.
    VIRCHOWS ARCHIV, 2012, 461 : S244 - S245
  • [49] HER2 ASSESSMENT ON CORE BIOPSIES USING MONOCLONAL ANTIBODY CB11 ACCURATELY DETERMINES HER2 STATUS IN BREAST CARCINOMA
    Purdie, C. A.
    Jordan, L.
    McCullough, J.
    Edwards, S.
    Cunningham, J.
    Grant, A.
    Pratt, N.
    Thompson, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 38 - 38
  • [50] Fynomer-antibody fusions targeting HER2 and CD3 for selective killing of HER2 overexpressing tumor cells.
    Woods, Richard
    Brack, Simon
    Klupsch, Kristina
    Wuellner, Ulrich
    Buller, Fabian
    Santimaria, Roger
    Attinger-Toller, Isabella
    Koenig-Friedrich, Susann
    Zbinden, Irene
    Bertschinger-Ehrler, Julian
    Grabulovski, Dragon
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)